Please login to the form below

evolucumab

This page shows the latest evolucumab news and features for those working in and with pharma, biotech and healthcare.

Looks to boost sales after trial shows clear clinical advantage of PCSK9 inhibitor over statins

SMC rejects Amgen's Repatha over lack of outcomes data

The Scottish Medicines Consortium (SMC) has turned down Amgen's cholesterol-lowering treatment Repatha (evolucumab), citing a lack of “ robust” data.
NICE persuaded to back Praluent as well as Repatha

drug. The scheme includes an undisclosed discount to the NHS and allows NICE to back Praluent and Amgen's rival Repatha (evolucumab), which had already agreed a price cut, in new

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Home based, Editorial Team Leader, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Senior Medical Writer, Medical Communications: Excellent package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Principal Medical Writer, Medical Communications: Excellent package

Add my company

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....